Alosetron for irritable bowel syndrome - Reply

AW Mangel

RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.

Alosetron for irritable bowel syndrome - Reply

Mangel, AW. (2000). Alosetron for irritable bowel syndrome - Reply. Lancet, 356(9246), 2009-2010.

Copy citation

Recent Publications

Article

Treatment preferences among patients with mild-to-moderate atopic dermatitis

Article

Multifaceted risk for non-suicidal self-injury only versus suicide attempt in a population-based cohort of adults

Article

Spatiotemporal analysis exploring the effect of law enforcement drug market disruptions on overdose, Indianapolis, Indiana, 2020-2021

Article

Protocol for the formative phase of a trial (SHE-CAN) to test co-designed implementation strategies for HPV-based cervical screening among vulnerable women in two diverse settings in India

Alosetron for irritable bowel syndrome - Reply

Publications Info

Recent Publications

Treatment preferences among patients with mild-to-moderate atopic dermatitis

Multifaceted risk for non-suicidal self-injury only versus suicide attempt in a population-based cohort of adults

Spatiotemporal analysis exploring the effect of law enforcement drug market disruptions on overdose, Indianapolis, Indiana, 2020-2021

Protocol for the formative phase of a trial (SHE-CAN) to test co-designed implementation strategies for HPV-based cervical screening among vulnerable women in two diverse settings in India

Partner With Us

Site